Ordered accumulation of mutations in HIV protease confers resistance to ritonavir - PubMed (original) (raw)

M Korneyeva, Q Gao, S Vasavanonda, P J Schipper, H M Mo, M Markowitz, T Chernyavskiy, P Niu, N Lyons, A Hsu, G R Granneman, D D Ho, C A Boucher, J M Leonard, D W Norbeck, D J Kempf

Affiliations

• PMID: 8673921
• DOI: 10.1038/nm0796-760

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

A Molla et al. Nat Med. 1996 Jul.

Abstract

Analysis of the HIV protease gene from the plasma of HIV-infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir. Mutants at valine-82, although insufficient to confer resistance, appeared first in most patients. Significant phenotypic resistance required multiple mutations in HIV protease, which emerged subsequently in an ordered, stepwise fashion. The appearance of resistance mutations was delayed in patients with higher plasma levels of ritonavir. Early mutants retained susceptibility to structurally diverse protease inhibitors, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.

PubMed Disclaimer

Similar articles

• Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
  Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E. Kempf DJ, et al. Antivir Ther. 2002 Sep;7(3):165-74. Antivir Ther. 2002. PMID: 12487383 Clinical Trial.
• Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
  Schmit JC, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J, Desmyter J, De Clercq E, Vandamme AM. Schmit JC, et al. AIDS. 1996 Aug;10(9):995-9. doi: 10.1097/00002030-199610090-00010. AIDS. 1996. PMID: 8853733
• The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
  Turner D, Schapiro JM, Brenner BG, Wainberg MA. Turner D, et al. Antivir Ther. 2004 Jun;9(3):301-14. Antivir Ther. 2004. PMID: 15259893 Review.
• Perspectives in HIV protease inhibitors.
  Leonard JM. Leonard JM. Adv Exp Med Biol. 1996;394:319-25. doi: 10.1007/978-1-4757-9209-6_29. Adv Exp Med Biol. 1996. PMID: 8815696 Review. No abstract available.

Cited by

• Crucial stages of protein folding through a solvable model: predicting target sites for enzyme-inhibiting drugs.
  Micheletti C, Cecconi F, Flammini A, Maritan A. Micheletti C, et al. Protein Sci. 2002 Aug;11(8):1878-87. doi: 10.1110/ps.3360102. Protein Sci. 2002. PMID: 12142442 Free PMC article.
• Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.
  Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. Prabu-Jeyabalan M, et al. J Virol. 2006 Apr;80(7):3607-16. doi: 10.1128/JVI.80.7.3607-3616.2006. J Virol. 2006. PMID: 16537628 Free PMC article.
• Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.
  Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. Charpentier C, et al. J Virol. 2004 Apr;78(8):4234-47. doi: 10.1128/jvi.78.8.4234-4247.2004. J Virol. 2004. PMID: 15047838 Free PMC article.
• Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.
  Valentin A, Morrow M, Poirier RH, Aleman K, Little R, Yarchoan R, Pavlakis GN. Valentin A, et al. AIDS Res Hum Retroviruses. 2010 Jan;26(1):79-88. doi: 10.1089/aid.2009.0044. AIDS Res Hum Retroviruses. 2010. PMID: 20059395 Free PMC article.
• An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.
  Poon AF, Lewis FI, Pond SL, Frost SD. Poon AF, et al. PLoS Comput Biol. 2007 Nov;3(11):e231. doi: 10.1371/journal.pcbi.0030231. Epub 2007 Oct 11. PLoS Comput Biol. 2007. PMID: 18039027 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Stanford HIV Drug Resistance Database